Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) — 分析摘要
Teva Pharmaceutical Industries Limited American Depositary Shares（TEVA）的市值为43.84十亿美元，最近一年的营收同比增长了+4.3%。净利润率为8.2%。当前市盈率为62.1倍。
核心要点
- 营收同比变化+4.3%
- 净利润率8.2%
- 市盈率62.1倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，TEVA的营收增长为+4.3%，市盈率为62.1倍。
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示重点关注
当前存在需要关注的风险信号，应与估值结果一并解读。
流动比率为 0.88x — 流动负债超过流动资产
净利润较上一期下降 49.9%。
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
32,842
总部
TEL AVIV
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.34
股息收益率
0.93%
股息历史
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。